A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study, in ...
Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout. The novel formulation of the stalwart ...
Stay up to date with the latest composites news directly in your inbox. Subscribe for free to the JEC Composites International and French e-Letters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback